Propanc Biopharma (PPCB) Long-Term Debt Issuances (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Long-Term Debt Issuances of -$25000.0 for Q4 2025, down 356.91% year-over-year from $9731.0 in Q4 2024, and down 125.0% quarter-over-quarter from $100000.0 in Q3 2025.
Propanc Biopharma (PPCB) Long-Term Debt Issuances (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Long-Term Debt Issuances for 15 consecutive years, with -$25000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances fell 356.91% year-over-year to -$25000.0; the TTM figure through Dec 2025 stood at $117788.0 (up 30.81% YoY), while the FY2025 annual figure was $122788.0, down 35.37% from the prior year.
- Long-Term Debt Issuances declined to -$25000.0 in Q4 2025 per PPCB's latest filing, from $100000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $345750.0 in Q3 2022 and bottomed at -$50315.0 in Q4 2023.
- Historically, Long-Term Debt Issuances has averaged $103292.7 across 5 years, with a median of $80000.0 in 2024.
- On a YoY basis, Long-Term Debt Issuances climbed as much as 490.79% in 2025 and fell as far as 356.91% in 2025.
- Propanc Biopharma's Long-Term Debt Issuances stood at $254500.0 in 2021, then plunged by 80.35% to $50000.0 in 2022, then sank by 200.63% to -$50315.0 in 2023, then soared by 119.34% to $9731.0 in 2024, then plunged by 356.91% to -$25000.0 in 2025.
- Business Quant data shows PPCB's Long-Term Debt Issuances at -$25000.0 in Q4 2025, $100000.0 in Q3 2025, and $24388.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25,000.00 |
| Dec 31, 2025 | -25,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 24,388.00 |
| Jun 30, 2025 | 24,388.00 |
| Mar 31, 2025 | 18,400.00 |
| Mar 31, 2025 | 18,400.00 |
| Dec 31, 2024 | 9,731.00 |
| Dec 31, 2024 | 9,731.00 |
| Sep 30, 2024 | 60,000.00 |
| Sep 30, 2024 | 60,000.00 |
| Jun 30, 2024 | 4,128.00 |
| Jun 30, 2024 | 4,128.00 |
| Mar 31, 2024 | 16,187.00 |
| Mar 31, 2024 | 16,187.00 |
| Dec 31, 2023 | -50,315.00 |
| Dec 31, 2023 | -50,315.00 |
| Sep 30, 2023 | 220,000.00 |
| Sep 30, 2023 | 220,000.00 |